733 related articles for article (PubMed ID: 14623544)
41. Steroid sulfatase inhibitors: promising new therapy for breast cancer.
Sadozai H
J Pak Med Assoc; 2013 Apr; 63(4):509-15. PubMed ID: 23905452
[TBL] [Abstract][Full Text] [Related]
42. Estrogen O-sulfamates and their analogues: Clinical steroid sulfatase inhibitors with broad potential.
Thomas MP; Potter BV
J Steroid Biochem Mol Biol; 2015 Sep; 153():160-9. PubMed ID: 25843211
[TBL] [Abstract][Full Text] [Related]
43. Stimulation of MCF-7 breast cancer cell proliferation by estrone sulfate and dehydroepiandrosterone sulfate: inhibition by novel non-steroidal steroid sulfatase inhibitors.
Billich A; Nussbaumer P; Lehr P
J Steroid Biochem Mol Biol; 2000; 73(5):225-35. PubMed ID: 11070351
[TBL] [Abstract][Full Text] [Related]
44. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
[TBL] [Abstract][Full Text] [Related]
45. Steroid sulfatase in breast carcinoma and change of serum estrogens levels after operation.
Tsunoda Y; Shimizu Y; Tsunoda A; Takimoto M; Sakamoto MA; Kusano M
Acta Oncol; 2006; 45(5):584-9. PubMed ID: 16864173
[TBL] [Abstract][Full Text] [Related]
46. Steroid sulfatase: a pivotal player in estrogen synthesis and metabolism.
Purohit A; Woo LW; Potter BV
Mol Cell Endocrinol; 2011 Jul; 340(2):154-60. PubMed ID: 21693170
[TBL] [Abstract][Full Text] [Related]
47. The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy.
Day JM; Purohit A; Tutill HJ; Foster PA; Woo LW; Potter BV; Reed MJ
Ann N Y Acad Sci; 2009 Feb; 1155():80-7. PubMed ID: 19250195
[TBL] [Abstract][Full Text] [Related]
48. Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers.
Hanamura T; Niwa T; Gohno T; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2014 Jan; 143(1):69-80. PubMed ID: 24292869
[TBL] [Abstract][Full Text] [Related]
49. Aromatase inhibitors in the treatment of breast cancer.
Brueggemeier RW; Hackett JC; Diaz-Cruz ES
Endocr Rev; 2005 May; 26(3):331-45. PubMed ID: 15814851
[TBL] [Abstract][Full Text] [Related]
50. Estrone sulfatase and its inhibitors.
Aidoo-Gyamfi K; Cartledge T; Shah K; Ahmed S
Anticancer Agents Med Chem; 2009 Jul; 9(6):599-612. PubMed ID: 19601744
[TBL] [Abstract][Full Text] [Related]
51. Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
Chetrite GS; Thole HH; Philippe JC; Pasqualini JR
Anticancer Res; 2004; 24(3a):1433-8. PubMed ID: 15274306
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives.
Phan CM; Liu Y; Kim BM; Mostafa Y; Taylor SD
Bioorg Med Chem; 2011 Oct; 19(20):5999-6005. PubMed ID: 21925885
[TBL] [Abstract][Full Text] [Related]
53. Development of (p-O-sulfamoyl)-N-alkanoyl-phenylalkyl amines as non-steroidal estrone sulfatase inhibitors.
Kolli A; Chu GH; Rhodes ME; Inoue K; Selcer KW; Li PK
J Steroid Biochem Mol Biol; 1999 Jan; 68(1-2):31-40. PubMed ID: 10215035
[TBL] [Abstract][Full Text] [Related]
54. Aromatase and COX-2 expression in human breast cancers.
Brodie AM; Lu Q; Long BJ; Fulton A; Chen T; Macpherson N; DeJong PC; Blankenstein MA; Nortier JW; Slee PH; van de Ven J; van Gorp JM; Elbers JR; Schipper ME; Blijham GH; Thijssen JH
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):41-7. PubMed ID: 11850206
[TBL] [Abstract][Full Text] [Related]
55. Recent developments of steroid sulfatase inhibitors as anti-cancer agents.
Foster PA; Reed MJ; Purohit A
Anticancer Agents Med Chem; 2008 Oct; 8(7):732-8. PubMed ID: 18855575
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer.
Foster PA; Chander SK; Parsons MF; Newman SP; Woo LW; Potter BV; Reed MJ; Purohit A
Breast Cancer Res Treat; 2008 Sep; 111(1):129-38. PubMed ID: 17914670
[TBL] [Abstract][Full Text] [Related]
57. Aromatase inhibitors: rationale for use following antiestrogen therapy.
Yue W; Santen RJ
Semin Oncol; 1996 Aug; 23(4 Suppl 9):21-7. PubMed ID: 8824461
[TBL] [Abstract][Full Text] [Related]
58. Breast cancer aromatase expression evaluated by the novel antibody 677: correlations to intra-tumor estrogen levels and hormone receptor status.
Geisler J; Suzuki T; Helle H; Miki Y; Nagasaki S; Duong NK; Ekse D; Aas T; Evans DB; Lønning PE; Sasano H
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):237-41. PubMed ID: 19883757
[TBL] [Abstract][Full Text] [Related]
59. Nonsteroidal aromatase inhibitors for the treatment of breast cancer: an update.
Gobbi S; Rampa A; Belluti F; Bisi A
Anticancer Agents Med Chem; 2014 Jan; 14(1):54-65. PubMed ID: 23869785
[TBL] [Abstract][Full Text] [Related]
60. Gonadotropins stimulate growth of MCF-7 human breast cancer cells by promoting intracellular conversion of adrenal androgens to estrogens.
Tanaka Y; Kuwabara K; Okazaki T; Fujita T; Oizumi I; Kaiho S; Ogata E
Oncology; 2000; 59 Suppl 1():19-23. PubMed ID: 11096352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
